2 Reasons to Like ASTH and 1 to Stay Skeptical

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

ASTH Cover Image

The past six months have been a windfall for Astrana Health’s shareholders. The company’s stock price has jumped 79%, hitting $49.01 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Is it too late to buy ASTH? Find out in our full research report, it’s free.

Why Does Astrana Health Spark Debate?

Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ: ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.

Two Positive Attributes:

1. Skyrocketing Revenue Shows Strong Momentum

Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Thankfully, Astrana Health’s 38.3% annualized revenue growth over the last five years was incredible. Its growth surpassed the average healthcare company and shows its offerings resonate with customers.

Astrana Health Quarterly Revenue

2. Outstanding Long-Term EPS Growth

We track the long-term change in earnings per share (EPS) because it highlights whether a company’s growth is profitable.

Astrana Health’s EPS grew at a spectacular 13.2% compounded annual growth rate over the last five years. This performance was better than most healthcare businesses.

Astrana Health Trailing 12-Month EPS (Non-GAAP)

One Reason to Be Careful:

New Investments Fail to Bear Fruit as ROIC Declines

A company’s ROIC, or return on invested capital, shows how much operating profit it makes compared to the money it has raised (debt and equity).

Unfortunately, Astrana Health’s ROIC has decreased significantly over the last few years. Only time will tell if its new bets can bear fruit and potentially reverse the trend.

Astrana Health Trailing 12-Month Return On Invested Capital

Final Judgment

Astrana Health’s merits more than compensate for its flaws, and with the recent rally, the stock trades at 15.8× forward P/E (or $49.01 per share). Is now the time to buy despite the apparent froth? See for yourself in our full research report, it’s free.

Stocks We Like Even More Than Astrana Health

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  256.02
+8.53 (3.45%)
AAPL  325.19
+10.33 (3.28%)
AMD  517.51
-30.62 (-5.59%)
BAC  61.59
+0.98 (1.61%)
GOOG  368.99
+11.66 (3.26%)
META  680.76
+19.72 (2.98%)
MSFT  397.56
+12.63 (3.28%)
NVDA  209.03
-2.77 (-1.31%)
ORCL  131.72
+3.78 (2.95%)
TSLA  396.90
+0.72 (0.18%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.